Background Heart failure with mildly reduced or preserved ejection fraction (hereafter
referred to as HFpEF) is the most common type of heart failure and is associated with a high …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

Background Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse
cardiovascular events (MACE) in people with overweight or obesity, but the effects of this …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Background Many therapies for heart failure (HF) have shown differential impact across the
spectrum of left ventricular ejection fraction (LVEF). Objectives In this prespecified analysis …

In the STEP-HFpEF trial, semaglutide improved symptoms, physical limitations and exercise
function and reduced body weight in patients with obesity phenotype of heart failure and …

BACKGROUND: Patients with heart failure (HF) with preserved ejection fraction (HFpEF)
and obesity experience a high burden of symptoms and functional impairment, and a poor …

Abstract Background In the Semaglutide Treatment Effect in People with obesity and HFpEF
(STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms …

Background The majority of patients with heart failure with preserved ejection fraction
(HFpEF) have the obesity phenotype, but no therapies specifically targeting obesity in …

Background People with type 2 diabetes (T2D) and chronic kidney disease (CKD) are at
high risk for heart failure (HF) and premature death from cardiovascular (CV) causes. The …